1. Home
  2. UP vs SNDX Comparison

UP vs SNDX Comparison

Compare UP & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wheels Up Experience Inc.

UP

Wheels Up Experience Inc.

HOLD

Current Price

$8.81

Market Cap

182.3M

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$19.63

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UP
SNDX
Founded
2013
2005
Country
United States
United States
Employees
1250
298
Industry
Aerospace
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
182.3M
1.8B
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
UP
SNDX
Price
$8.81
$19.63
Analyst Decision
Strong Buy
Analyst Count
0
13
Target Price
N/A
$38.69
AVG Volume (30 Days)
238.2K
1.5M
Earning Date
05-12-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
11.56
EPS
N/A
N/A
Revenue
N/A
$172,352,000.00
Revenue This Year
N/A
$107.19
Revenue Next Year
N/A
$41.88
P/E Ratio
N/A
N/A
Revenue Growth
N/A
627.84
52 Week Low
$0.36
$8.59
52 Week High
$9.70
$25.59

Technical Indicators

Market Signals
Indicator
UP
SNDX
Relative Strength Index (RSI) 71.14 41.06
Support Level $0.79 $19.28
Resistance Level N/A $22.40
Average True Range (ATR) 1.03 0.88
MACD 0.15 0.05
Stochastic Oscillator 84.65 18.56

Price Performance

Historical Comparison
UP
SNDX

About UP Wheels Up Experience Inc.

Wheels Up Experience Inc is a provider of on-demand private aviation. The company offers a private aviation solution with a large and diverse aircraft fleet, delivered through a mix of charter solutions and its membership program that utilizes its controlled aircraft fleet and a network of safety-vetted charter operators. Through its partnership firm, it provides members and customers with an offering across private and premium commercial travel. It generates the majority of its revenue from member and customer flights through its membership program and charter solutions, as well as from membership fees and other activities and services, including group charter flights, cargo flights, and special missions. Geographically, the company generates maximum revenue from the United States.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: